One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients

F. David Fortuin, Peter Vale, Douglas W. Losordo, James Symes, Giacomo A. DeLaria, J. Jeffrey Tyner, Gary L. Schaer, Robert March, R. Jeffrey Snell, Timothy D. Henry, Joseph Van Camp, John J. Lopez, Wayne Richenbacher, Jeffrey M. Isner, Richard A. Schatz

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

This phase I open label, dose-escalating study shows that gene transfer of vascular endothelial growth factor-2 naked deoxyribonucleic acid by direct myocardial injection by way of thoracotomy in patients with Canadian Cardiovascular Society class 3 or 4 angina is feasible and safe. The procedure is well tolerated, with few major adverse cardiac events at 1 year, and without complications directly related to gene expression. In this prospective, nonblinded study, the procedure is associated with clinical improvement; however, there was no angiographic evidence of angiogenesis and there is a great potential for a sham or placebo effect in the study patients. A randomized phase III trial is underway that will help determine the efficacy of vascular endothelial growth factor-2 gene transfer in "no-option" patients.

Original languageEnglish (US)
Pages (from-to)436-439
Number of pages4
JournalAmerican Journal of Cardiology
Volume92
Issue number4
DOIs
StatePublished - Aug 15 2003
Externally publishedYes

Fingerprint

Thoracotomy
Vascular Endothelial Growth Factor A
Plasmids
DNA
Genes
Placebo Effect
Prospective Studies
Gene Expression
Injections

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. / Fortuin, F. David; Vale, Peter; Losordo, Douglas W.; Symes, James; DeLaria, Giacomo A.; Tyner, J. Jeffrey; Schaer, Gary L.; March, Robert; Snell, R. Jeffrey; Henry, Timothy D.; Van Camp, Joseph; Lopez, John J.; Richenbacher, Wayne; Isner, Jeffrey M.; Schatz, Richard A.

In: American Journal of Cardiology, Vol. 92, No. 4, 15.08.2003, p. 436-439.

Research output: Contribution to journalArticle

Fortuin, FD, Vale, P, Losordo, DW, Symes, J, DeLaria, GA, Tyner, JJ, Schaer, GL, March, R, Snell, RJ, Henry, TD, Van Camp, J, Lopez, JJ, Richenbacher, W, Isner, JM & Schatz, RA 2003, 'One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients', American Journal of Cardiology, vol. 92, no. 4, pp. 436-439. https://doi.org/10.1016/S0002-9149(03)00661-1
Fortuin, F. David ; Vale, Peter ; Losordo, Douglas W. ; Symes, James ; DeLaria, Giacomo A. ; Tyner, J. Jeffrey ; Schaer, Gary L. ; March, Robert ; Snell, R. Jeffrey ; Henry, Timothy D. ; Van Camp, Joseph ; Lopez, John J. ; Richenbacher, Wayne ; Isner, Jeffrey M. ; Schatz, Richard A. / One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. In: American Journal of Cardiology. 2003 ; Vol. 92, No. 4. pp. 436-439.
@article{3db2d5ad4e1c42c29dbc104964d29065,
title = "One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients",
abstract = "This phase I open label, dose-escalating study shows that gene transfer of vascular endothelial growth factor-2 naked deoxyribonucleic acid by direct myocardial injection by way of thoracotomy in patients with Canadian Cardiovascular Society class 3 or 4 angina is feasible and safe. The procedure is well tolerated, with few major adverse cardiac events at 1 year, and without complications directly related to gene expression. In this prospective, nonblinded study, the procedure is associated with clinical improvement; however, there was no angiographic evidence of angiogenesis and there is a great potential for a sham or placebo effect in the study patients. A randomized phase III trial is underway that will help determine the efficacy of vascular endothelial growth factor-2 gene transfer in {"}no-option{"} patients.",
author = "Fortuin, {F. David} and Peter Vale and Losordo, {Douglas W.} and James Symes and DeLaria, {Giacomo A.} and Tyner, {J. Jeffrey} and Schaer, {Gary L.} and Robert March and Snell, {R. Jeffrey} and Henry, {Timothy D.} and {Van Camp}, Joseph and Lopez, {John J.} and Wayne Richenbacher and Isner, {Jeffrey M.} and Schatz, {Richard A.}",
year = "2003",
month = "8",
day = "15",
doi = "10.1016/S0002-9149(03)00661-1",
language = "English (US)",
volume = "92",
pages = "436--439",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients

AU - Fortuin, F. David

AU - Vale, Peter

AU - Losordo, Douglas W.

AU - Symes, James

AU - DeLaria, Giacomo A.

AU - Tyner, J. Jeffrey

AU - Schaer, Gary L.

AU - March, Robert

AU - Snell, R. Jeffrey

AU - Henry, Timothy D.

AU - Van Camp, Joseph

AU - Lopez, John J.

AU - Richenbacher, Wayne

AU - Isner, Jeffrey M.

AU - Schatz, Richard A.

PY - 2003/8/15

Y1 - 2003/8/15

N2 - This phase I open label, dose-escalating study shows that gene transfer of vascular endothelial growth factor-2 naked deoxyribonucleic acid by direct myocardial injection by way of thoracotomy in patients with Canadian Cardiovascular Society class 3 or 4 angina is feasible and safe. The procedure is well tolerated, with few major adverse cardiac events at 1 year, and without complications directly related to gene expression. In this prospective, nonblinded study, the procedure is associated with clinical improvement; however, there was no angiographic evidence of angiogenesis and there is a great potential for a sham or placebo effect in the study patients. A randomized phase III trial is underway that will help determine the efficacy of vascular endothelial growth factor-2 gene transfer in "no-option" patients.

AB - This phase I open label, dose-escalating study shows that gene transfer of vascular endothelial growth factor-2 naked deoxyribonucleic acid by direct myocardial injection by way of thoracotomy in patients with Canadian Cardiovascular Society class 3 or 4 angina is feasible and safe. The procedure is well tolerated, with few major adverse cardiac events at 1 year, and without complications directly related to gene expression. In this prospective, nonblinded study, the procedure is associated with clinical improvement; however, there was no angiographic evidence of angiogenesis and there is a great potential for a sham or placebo effect in the study patients. A randomized phase III trial is underway that will help determine the efficacy of vascular endothelial growth factor-2 gene transfer in "no-option" patients.

UR - http://www.scopus.com/inward/record.url?scp=0042564700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042564700&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(03)00661-1

DO - 10.1016/S0002-9149(03)00661-1

M3 - Article

C2 - 12914874

AN - SCOPUS:0042564700

VL - 92

SP - 436

EP - 439

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 4

ER -